LLIT Lianluo Smart Ltd

⁽¹⁾          Includes (i) 11,111,111 common shares, par value $0.002731 per share issued and outstanding as of August 18, 2016 and (ii) 1,000,000 common shares underlying warrants to purchase common shares, which are exercisable within 60 days after the date hereof, in each case as disclosed in the share purchase agreement, dated as of April 28, 2016 (the “SPA”), by and between the Issuer and Hangzhou Liaison Interactive Information Technology Co., Ltd. (“the Reporting Person”) and amendment no. 1 to share purchase agreement, dated June 28, 2016 (the “SPA Amendment No. 1”), by and between the Issuer and the Reporting Person.

⁽²⁾          Based on an aggregate of 18,312,856 common shares, including (i) 6,201,745 common shares issued and outstanding as of April 18, 2016 as disclosed in the SPA and the SPA Amendment No. 1, (ii) 11,111,111 common shares newly issued by the Issuer to the Reporting Person pursuant to the SPA and the SPA Amendment No. 1, and (iii) 1,000,000 common shares underlying warrants to purchase common shares, which are exercisable within 60 days after the date hereof by the Reporting Person. Based on the foregoing, the percentage of common shares beneficially owned by the Reporting Person equals 66.1%.

ITEM 1.          SECURITY AND ISSUER

This Schedule 13D (this “Schedule 13D ”) relates to the common shares, par value $0.002731 per share (the “Shares”) of Dehaier Medical Systems Limited, a British Virgin Islands company (the “Company” or “Issuer”). The Issuer’s principle place of business is Room 501, 83 Fuxing Road, Haidian District, Beijing 100856, People’s Republic of China.

ITEM 2.          IDENTITY AND BACKGROUND

(a)          This Schedule 13D is being filed pursuant to Rule 13d-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) by Hangzhou Liaison Interactive Information Technology Co., Ltd, a company organized under the laws of the People’s Republic of China (the “Reporting Person”).

(b)          The principle business address and principle executive offices of the Reporting Person is 18/F, Xintu Tower, 451, Wulianwang Street, Binjiang District, Hangzhou, Zhejiang Province 310051, People’s Republic of China. The name, business address, citizenship and present principal occupation or employment of each executive officer and each member of the board of directors of the Reporting Person are set forth on Schedule A hereto and are incorporated herein by reference.

(c)          The principal business of the Reporting Person is research, development and operation of mobile terminal operation systems, middleware platforms and related applications.

(d) – (e) During the last five years, none of the Reporting Person nor, to the knowledge of the Reporting Person, any person named in Schedule A (a) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or (b) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

ITEM 3.          SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

Pursuant to the share purchase agreement, dated as of April 28, 2016 (the “SPA”) and amendment no. 1 to share purchase agreement, dated June 28, 2016 (the “SPA Amendment No. 1”), in each case by and between the Issuer and the Reporting Person, upon the closing on August 18, 2016, the Reporting Person acquired for an aggregate purchase price of $20,000,000 (i) 11,111,111 Shares newly issued by the Issuer (the “Issued Shares”) at approximately $1.80 per share and (ii) warrants to purchase 1,000,000 Shares of the Issuer at a purchase price of $2.20 per share (the “Issued Warrants”) in consideration of the payment by the Reporting Person of the purchase price. The information disclosed in this paragraph does not purport to be complete and is qualified in its entirety by reference to the SPA and the SPA Amendment No. 1, copies of which are filed as Exhibit 7.01 and Exhibit 7.02 and are incorporated herein by reference in their entirety.

In connection with the closing under the SPA and the SPA Amendment No. 1, the Reporting Person funded the purchase price paid to the Issuer under the SPA and the SPA Amendment No. 1 using the Reporting Person’s working capital. Such funding was made in the form of an equity contribution of $20,000,000 to the Issuer.

The information set forth or incorporated by reference in Item 5 of this Schedule 13D is hereby incorporated by reference in this Item 3.

ITEM 4.          PURPOSE OF TRANSACTION

The Issuer and the Reporting Person entered into the SPA on April 28, 2016 and the SPA Amendment No. 1 on June 28, 2016, respectively. Pursuant to the SPA and the SPA Amendment No. 1, on August 18, 2016, the Reporting Person acquired (i) 11,111,111 Issued Shares (ii) 1,000,000 Issued Warrants, which are exercisable within 60 days after the date hereof, for an aggregate purchase price of $20,000,000.

The purpose of the transactions contemplated under the SPA and the SPA Amendment No. 1 is to acquire the Issued Shares and Issued Warrants of the Issuer and to gain control of the Issuer. The information disclosed in this paragraph and the preceding two paragraphs is qualified in its entirety by reference to the SPA and the SPA Amendment No. 1, which are incorporated herein by reference in their entirety.

Item 3 and Item 6 of this Schedule 13D is incorporated herein by reference.

Other than described in Item 3 and Item 4 above, the Reporting Person have no plans or proposals which relate to or would result in any of the actions specified in paragraphs (a) through (j) of Item 4 of Schedule 13D. the Reporting Person may, at any time and from time to time, formulate other purposes, plans or proposals regarding the Issuer, or any other actions that could involve one or more of the types of the transactions that have one or more of the results described in paragraphs (a) through (j) of Item 4 of Schedule 13D.

ITEM 5.          INTEREST IN SECURITIES OF THE ISSUER

(a) – (b) The following disclosure is based on an aggregate of 18,312,856 Shares, including (i) 6,201,745 Shares issued and outstanding as of April 28, 2016 as disclosed in the SPA and the SPA Amendment No. 1, (ii) 11,111,111 Shares newly issued by the Issuer to the Reporting Person pursuant to the SPA and the SPA Amendment No. 1, and (iii) 1,000,000 Shares issuable underlying warrants to purchase Shares, which are exercisable within 60 days after the date hereof by the Reporting Person.

Pursuant to Rule 13-d under the Exchange Act, the Reporting Person may be deemed to beneficially own 12,111,111 Shares, including (i) 11,111,111 Shares and (ii) 1,000,000 Shares issuable underlying warrant to purchase Shares, which are exercisable within 60 days after the date hereof by the Reporting Person, and representing 66.1% of the total outstanding Shares of the Issuer as of August 18, 2016. the Reporting Person holds warrants to acquire from the Issuer 1,000,000 Shares at a purchase price of $2.20 per share. The warrants are exercisable by the Reporting Person or its designee in whole or in part at any time after the date hereof.

The Reporting Person is the sole party with voting and dispositive power with regard to the 12,111,111 Shares described under this Schedule 13D.

The information contained on the cover pages to this Schedule 13D, and Item 2, Item 3, Item 4 and Item 6 of this Schedule 13D are incorporated herein by reference.

(c)          To the best knowledge of the Reporting Person, except as described herein, the Reporting Person has not effected any transaction in the Shares during the 60-day period prior to the filing of this Schedule 13D.

(d)          To the best knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares that are the subject of this Schedule 13D.

(e)          Not applicable.

ITEM 6.          CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

The descriptions of the SPA under Item 3, Item 4 and Item 5 are incorporated herein by reference. The summary of certain provisions of such agreements in this Schedule 13D are not intended to be complete and are qualified in their entirety by reference to the full text of such agreement.

To the best of the knowledge of the Reporting Person, except as provided herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise), including, but not limited to, transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, or the giving or withholding of proxies, between the Reporting Person and any other person, with respect to any securities of the Issuer, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities other than standard default and similar provisions contained in loan agreements.

ITEM 7.          MATERIAL TO BE FILED AS EXHIBITS

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: August 23, 2016

[Signature Page to Schedule 13D]

Schedule A

EXECUTIVE OFFICERS AND CONTROL PERSONS OF THE REPORTING PERSON

The following table set forth the names, citizenship, and present principal occupation or employment of each director and executive officer of Hangzhou Liaison Interactive Information Technology Co., Ltd. Unless otherwise noted, the business address for each person listed below is Hangzhou Liaison Interactive Information Technology Co., Ltd., 18/F, Xintu Tower, 451, Wulianwang Street, Binjiang District, Hangzhou, Zhejiang Province 310051, People’s Republic of China.